SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced that the Company will issue its financial results for the first quarter of 2015 on Tuesday, May 12, 2015, after the close of the market, and will hold a conference call on this day at 4:30 p.m. ET to discuss the financial results and provide a company update.
The conference call will be hosted by Michael Nall, President and Chief Executive Officer, and Bill Kachioff, Chief Financial Officer. The conference call can be accessed by dialing 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. The conference ID number for both is 13608923. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.biocept.com.
After the live webcast, the event will remain archived on Biocept's website for one year. In addition, a telephonic replay of the call will be available until May 19, 2015. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13608923.
About Biocept
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in CTCs and in plasma (ctDNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-GATM test for gastric cancer, OncoCEE-BRTM test for breast cancer and OncoCEE-LUTM test for non-small cell lung cancer and plans to introduce CLIA validated tests for colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.